Stock Scorecard



Stock Summary for Mereo Biopharma Group Plc (MREO) - $1.52 as of 8/12/2025 5:23:14 AM EST

Total Score

8 out of 30

Safety Score

23 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for MREO

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for MREO

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for MREO

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for MREO

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for MREO (23 out of 100)

Stock Price Rating (Max of 10) 2
Historical Stock Price Rating (Max of 10) 2
Stock Price Trend (Max of 10) 0
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for MREO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO - Mereo BioPharma Group ( NASDAQ:MREO ) 8/13/2025 3:45:00 PM
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights 8/12/2025 11:35:00 AM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO - Mereo BioPharma Group ( NASDAQ:MREO ) 8/9/2025 4:26:00 PM
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y 8/6/2025 3:43:00 PM
Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks - Ultragenyx Pharmaceutical ( NASDAQ:RARE ) 7/28/2025 5:16:00 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO - Mereo BioPharma Group ( NASDAQ:MREO ) 7/28/2025 3:53:00 PM
Bispecific Antibodies Market Set to Surge to $163.15 Billion by 2032, Driven by a Robust 40.1% CAGR | Roche, Amgen, and Johnson & Johnson at the Forefront: AnalystView Market Insights 7/22/2025 7:20:00 AM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE - Ultragenyx Pharmaceutical ( NASDAQ:RARE ) 7/18/2025 4:00:00 PM
Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA 7/15/2025 12:28:00 PM
Crude Oil Down Over 2%; Delta Air Lines Posts Upbeat Earnings - BIT Mining ( NYSE:BTCM ) , Above Food Ingredients ( NASDAQ:ABVE ) 7/10/2025 5:04:00 PM

Financial Details for MREO

Company Overview

Ticker MREO
Company Name Mereo Biopharma Group Plc
Country USA
Description Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops and markets therapeutic products for the treatment of oncology and rare diseases in the UK and internationally. The company is headquartered in London, the United Kingdom.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 3/31/2025
Next Earnings Date 10/7/2025

Stock Price History

Last Day Price 1.52
Price 4 Years Ago 1.60
Last Day Price Updated 8/12/2025 5:23:14 AM EST
Last Day Volume 1,822,899
Average Daily Volume 3,406,863
52-Week High 5.02
52-Week Low 1.51
Last Price to 52 Week Low 0.66%

Valuation Measures

Trailing PE N/A
Industry PE 43.11
Sector PE 57.42
5-Year Average PE -48.03
Free Cash Flow Ratio 3.90
Industry Free Cash Flow Ratio 16.50
Sector Free Cash Flow Ratio 30.31
Current Ratio Most Recent Quarter 8.92
Total Cash Per Share 0.39
Book Value Per Share Most Recent Quarter 0.38
Price to Book Ratio 4.05
Industry Price to Book Ratio 34.22
Sector Price to Book Ratio 28.40
Price to Sales Ratio Twelve Trailing Months 598.13
Industry Price to Sales Ratio Twelve Trailing Months 107.50
Sector Price to Sales Ratio Twelve Trailing Months 32.19
Analyst Buy Ratings 6
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 159,000,000
Market Capitalization 241,680,000
Institutional Ownership 77.48%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -46.79%
Reported EPS 12 Trailing Months -0.35
Reported EPS Past Year -0.02
Reported EPS Prior Year -0.18
Net Income Twelve Trailing Months -47,189,000
Net Income Past Year -43,253,000
Net Income Prior Year -29,466,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 62,483,000
Total Cash Past Year 69,802,000
Total Cash Prior Year 57,421,000
Net Cash Position Most Recent Quarter 56,932,000
Net Cash Position Past Year 65,408,000
Long Term Debt Past Year 4,394,000
Long Term Debt Prior Year 4,394,000
Total Debt Most Recent Quarter 5,551,000
Equity to Debt Ratio Past Year 0.93
Equity to Debt Ratio Most Recent Quarter 0.92
Total Stockholder Equity Past Year 60,969,000
Total Stockholder Equity Prior Year 50,537,000
Total Stockholder Equity Most Recent Quarter 60,081,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -33,891,599
Free Cash Flow Per Share Twelve Trailing Months -0.21
Free Cash Flow Past Year -33,533,000
Free Cash Flow Prior Year -21,551,000

Options

Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.19
MACD Signal -0.20
20-Day Bollinger Lower Band 1.30
20-Day Bollinger Middle Band 2.21
20-Day Bollinger Upper Band 3.11
Beta 0.42
RSI 28.48
50-Day SMA 2.37
150-Day SMA 0.00
200-Day SMA 2.10

System

Modified 8/12/2025 5:23:15 AM EST